Estrogen therapy in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Endocrinology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) predominantly affects females, with sex hormones potentially influencing disease activity.
• Estrogen exposure has been anecdotally linked to SLE development or exacerbation, raising concerns about hormonal therapies.

Purpose of the Study:

• To evaluate the potential benefits and risks of exogenous estrogen use, including oral contraceptives (OCs) and hormone replacement therapy (HRT), in patients with SLE.
• To assess the safety and tolerability of hormonal therapies in SLE management, considering bone protection and fertility treatments.

Main Methods:

• Review of retrospective studies and clinical trial data concerning estrogen exposure and SLE.
• Analysis of potential benefits like bone protection with OCs in corticosteroid-treated patients.
• Consideration of hormonal therapies for fertility in SLE patients with stable disease and low thrombosis risk.

Main Results:

• While exogenous estrogens raise concerns in SLE, OCs may be well-tolerated and offer bone protection.
• Hormone replacement therapy use is limited by Women's Health Initiative trial findings, posing particular concern for SLE patients.
• Hormonal therapies may benefit SLE patients with stable disease and low thrombosis risk without increasing lupus activity.

Conclusions:

• Exogenous estrogen use in SLE requires careful consideration of individual patient factors, disease activity, and thrombosis risk.
• Further large-scale, prospective, double-blind, placebo-controlled studies are needed to establish definitive recommendations for hormonal therapies in SLE.
• Balancing the risks and benefits of estrogen therapy is crucial for managing SLE and associated conditions like osteoporosis.